Your browser doesn't support javascript.
Safety of biologics in inflammatory bowel disease patients with COVID-19.
Weissman, Simcha; Aziz, Muhammad; Smith, Wade-Lee; Elias, Sameh; Swaminath, Arun; Feuerstein, Joseph D.
  • Weissman S; Department of Medicine, Hackensack Meridian Health Palisades Medical Center, North Bergen, NJ, USA. Simchaweissman@gmail.com.
  • Aziz M; Division of Gastroenterology and Hepatology, University of Toledo Medical Center, Toledo, OH, USA.
  • Smith WL; Division of Gastroenterology and Hepatology, University of Toledo Medical Center, Toledo, OH, USA.
  • Elias S; Department of Medicine, Hackensack Meridian Health Palisades Medical Center, North Bergen, NJ, USA.
  • Swaminath A; Division of Gastroenterology, Inflammatory Bowel Disease Program, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
  • Feuerstein JD; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Int J Colorectal Dis ; 36(9): 2051-2055, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1270507
ABSTRACT

BACKGROUND:

Patients with Inflammatory bowel disease (IBD) remain highly concerned that either their disease or medications-namely, biologics-may increase the risk of severe coronavirus-2019 (COVID-19). We aimed to assess the safety of biologics in Inflammatory bowel disease (IBD) patients with COVID-19.

METHODS:

We systematically reviewed multiple databases to find relevant articles reporting the effect of biologics on "severe" COVID-19 in IBD patients. Those in the form of case series (> 10 patients), case-control, and cohort studies were included. Severe COVID-19 was defined as intensive care unit (ICU) admission, mechanical ventilation, and/or mortality. Pooled analysis with multivariate regression was performed.

RESULTS:

A total of 12 studies with 2681 patients were included. The proportion of females was (48.3%, 95% confidence interval (CI) 47.0-49.5%). The proportion of UC patients was (44.8%, 95% CI 41.0-48.5%). Overall, in IBD patients, the need for mechanical ventilation, intensive care unit (ICU) admission, and mortality was 5.1%, 6.1%, and 4.5%, respectively. Use of biologics did not show a moderating effect on mechanical ventilation (p = 0.68), ICU admission (p = 0.27), or mortality (p = 0.20).

CONCLUSIONS:

Our findings advocate for the continued biologic therapy in IBD patients during the COVID-19 pandemic. Nevertheless, the incidence, severity, and outcomes related to COVID-19 in IBD patients' needs to be reassessed as data continues to emerge.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Products / Inflammatory Bowel Diseases / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Reviews Limits: Female / Humans Language: English Journal: Int J Colorectal Dis Journal subject: Gastroenterology Year: 2021 Document Type: Article Affiliation country: S00384-021-03977-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Products / Inflammatory Bowel Diseases / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Reviews Limits: Female / Humans Language: English Journal: Int J Colorectal Dis Journal subject: Gastroenterology Year: 2021 Document Type: Article Affiliation country: S00384-021-03977-9